{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T02:14:07Z","timestamp":1781576047576,"version":"3.54.5"},"reference-count":105,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T00:00:00Z","timestamp":1544486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2SB1AI102396-06)."],"award-info":[{"award-number":["2SB1AI102396-06)."]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Hyperimmune globulin (HIG) has shown efficacy against human cytomegalovirus (HCMV) for both transplant and congenital transmission indications. Replicating that activity with a monoclonal antibody (mAb) offers the potential for improved consistency in manufacturing, lower infusion volume, and improved pharmacokinetics, as well as reduced risk of off-target reactivity leading to toxicity. HCMV pathology is linked to its broad cell tropism. The glycoprotein B (gB) envelope protein is important for infections in all cell types. Within gB, the antigenic determinant (AD)-2 Site I is qualitatively more highly-conserved than any other region of the virus. TRL345, a high affinity (Kd = 50 pM) native human mAb to this site, has shown efficacy in neutralizing the infection of fibroblasts, endothelial and epithelial cells, as well as specialized placental cells including trophoblast progenitor cells. It has also been shown to block the infection of placental fragments grown ex vivo, and to reduce syncytial spread in fibroblasts in vitro. Manufacturing and toxicology preparation for filing an IND (investigational new drug) application with the US Food and Drug Administration (FDA) are expected to be completed in mid-2019.<\/jats:p>","DOI":"10.3390\/ijms19123982","type":"journal-article","created":{"date-parts":[[2018,12,12]],"date-time":"2018-12-12T03:27:49Z","timestamp":1544585269000},"page":"3982","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["A Native Human Monoclonal Antibody Targeting HCMV gB (AD-2 Site I)"],"prefix":"10.3390","volume":"19","author":[{"given":"Michael M.","family":"McVoy","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Virginia Commonwealth University School of Medicine, P.O. Box 980163 MCV Station, Richmond, VA 23298-0163, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Tenorio","sequence":"additional","affiliation":[{"name":"Trellis Bioscience, LLC, 702 Marshall Street, Suite 614, Redwood City, CA 94063, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence M.","family":"Kauvar","sequence":"additional","affiliation":[{"name":"Trellis Bioscience, LLC, 702 Marshall Street, Suite 614, Redwood City, CA 94063, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,12,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3389\/fimmu.2013.00271","article-title":"Human T cell aging and the impact of persistent viral infections","volume":"4","author":"Fulop","year":"2013","journal-title":"Front. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.coi.2012.04.002","article-title":"The impact of CMV infection on survival in older humans","volume":"24","author":"Pawelec","year":"2012","journal-title":"Curr. Opin. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/TP.0b013e31829df29d","article-title":"Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"96","author":"Kotton","year":"2013","journal-title":"Transplantation"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e2016031","DOI":"10.4084\/mjhid.2016.031","article-title":"CMV in hematopoietic stem cell transplantation","volume":"8","year":"2016","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/cmi.2014.120","article-title":"The immunological underpinnings of vaccinations to prevent cytomegalovirus disease","volume":"12","author":"McCormick","year":"2015","journal-title":"Cell. Mol. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/bloodadvances.2018016493","article-title":"Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation","volume":"2","author":"Chen","year":"2018","journal-title":"Blood Adv."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"138","DOI":"10.12688\/f1000research.10276.1","article-title":"Cytomegalovirus in pregnancy and the neonate","volume":"6","author":"Emery","year":"2017","journal-title":"F1000Research"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1001\/jama.1986.03380140074025","article-title":"Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome","volume":"256","author":"Stagno","year":"1986","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1542\/peds.2013-2217","article-title":"Incidence and impact of cmv infection in very low birth weight infants","volume":"133","author":"Turner","year":"2014","journal-title":"Pediatrics"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/jmv.23954","article-title":"Maternal, fetal, and neonatal parameters for prognosis and counseling of HCMV congenital infection","volume":"86","author":"Zavattoni","year":"2014","journal-title":"J. Med. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/INF.0b013e31822d9640","article-title":"Congenital cytomegalovirus infection as a cause of sensorineural hearing loss in a highly immune population","volume":"30","author":"Yamamoto","year":"2011","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/07853890.1999.11904392","article-title":"Fetal origins of cardiovascular disease","volume":"31","author":"Barker","year":"1999","journal-title":"Ann. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/infdis\/jir121","article-title":"Human cytomegalovirus infection is detected frequently in stillbirths and is associated with fetal thrombotic vasculopathy","volume":"203","author":"Iwasenko","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/jmv.21293","article-title":"Detection of cytomegalovirus, parvovirus b19 and herpes simplex viruses in cases of intrauterine fetal death: Association with pathological findings","volume":"80","author":"Syridou","year":"2008","journal-title":"J. Med. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Kalil, A.C., Freifeld, A.G., Lyden, E.R., and Stoner, J.A. (2009). Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: An evidence-based reassessment of safety and efficacy. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0005512"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.placenta.2017.04.020","article-title":"Congenital cytomegalovirus infection undermines early development and functions of the human placenta","volume":"59","author":"Pereira","year":"2017","journal-title":"Placenta"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.ajpath.2012.08.003","article-title":"Cytomegalovirus impairs cytotrophoblast-induced lymphangiogenesis and vascular remodeling in an in vivo human placentation model","volume":"181","author":"Tabata","year":"2012","journal-title":"Am. J. Pathol."},{"key":"ref_18","first-page":"392","article-title":"Congenital cytomegalovirus infection\u2014A question of screening","volume":"9","author":"Rahav","year":"2007","journal-title":"Isr. Med. Assoc. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3390\/v6031049","article-title":"Genomic and functional characteristics of human cytomegalovirus revealed by next-generation sequencing","volume":"6","author":"Sijmons","year":"2014","journal-title":"Viruses"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1126\/science.1227919","article-title":"Decoding human cytomegalovirus","volume":"338","author":"Weisburd","year":"2012","journal-title":"Science (New York)"},{"key":"ref_21","first-page":"63","article-title":"Cytomegalovirus cell tropism","volume":"325","author":"Sinzger","year":"2008","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"8999","DOI":"10.1128\/JVI.01325-15","article-title":"Human cytomegalovirus gH\/gL\/gO promotes the fusion step of entry into all cell types, whereas gh\/gl\/ul128-131 broadens virus tropism through a distinct mechanism","volume":"89","author":"Zhou","year":"2015","journal-title":"J. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1128\/JVI.01910-07","article-title":"Characterization of the human cytomegalovirus gH\/gL\/UL128-131 complex that mediates entry into epithelial and endothelial cells","volume":"82","author":"Ryckman","year":"2008","journal-title":"J. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"18153","DOI":"10.1073\/pnas.0509201102","article-title":"Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism","volume":"102","author":"Wang","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1099\/vir.0.018994-0","article-title":"Sequential mutations associated with adaptation of human cytomegalovirus to growth in cell culture","volume":"91","author":"Dargan","year":"2010","journal-title":"J. Gen. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1128\/JVI.01500-15","article-title":"Viral regulation of cell tropism in human cytomegalovirus","volume":"90","author":"Li","year":"2016","journal-title":"J. Virol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Zhang, L., Zhou, M., Stanton, R., Kamil, J., and Ryckman, B.J. (2018). Expression levels of glycoprotein o (go) vary between strains of human cytomegalovirus, influencing the assembly of gH\/gL complexes and virion infectivity. J. Virol., 92.","DOI":"10.1128\/JVI.00606-18"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Renzette, N., Bhattacharjee, B., Jensen, J.D., Gibson, L., and Kowalik, T.F. (2011). Extensive genome-wide variability of human cytomegalovirus in congenitally infected infants. PLoS Pathog., 7.","DOI":"10.1371\/journal.ppat.1001344"},{"key":"ref_29","unstructured":"Kauvar, L.M., Pereira, L., Permar, S., Kowalik, T., Hamprecht, K., Adler, S.P., and McVoy, M.A. (2018, January 4\u20136). Trl345: A native human mab against cmv (gb: Ad-2 site I). Proceedings of the Cytomegalovirus Infection: Advancing Strategies for Prevention and Treatment, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/cid\/cix259","article-title":"Risk factors and outcomes of ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients","volume":"65","author":"Fisher","year":"2017","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M13-2729","article-title":"Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: A randomized trial","volume":"162","author":"Boeckh","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.blre.2017.01.002","article-title":"The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: Why the quest for meaningful prophylaxis still matters","volume":"31","author":"Chan","year":"2017","journal-title":"Blood Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1080\/17512433.2018.1500897","article-title":"Letermovir for the prevention of cytomegalovirus infection in adult cytomegalovirus-seropositive hematopoietic stem cell transplant recipients","volume":"11","author":"Foolad","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1128\/AAC.01596-09","article-title":"In vitro and in vivo activities of the novel anticytomegalovirus compound aic246","volume":"54","author":"Lischka","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","first-page":"269","article-title":"Letermovir and inhibitors of the terminase complex: A promising new class of investigational antiviral drugs against human cytomegalovirus","volume":"8","author":"Melendez","year":"2015","journal-title":"Infect. Drug Resist."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1128\/AAC.01794-13","article-title":"Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (aic246) exposure","volume":"58","author":"Goldner","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1128\/AAC.01623-15","article-title":"Rapid in vitro evolution of human cytomegalovirus ul56 mutations that confer letermovir resistance","volume":"59","author":"Chou","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Knoll, B.M., Seiter, K., Phillips, A., and Soave, R. (2018). Breakthrough cytomegalovirus pneumonia in hematopoietic stem cell transplant recipient on letermovir prophylaxis. Bone Marrow Transplant.","DOI":"10.1038\/s41409-018-0389-9"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/infdis\/jiv352","article-title":"Characterization of cytomegalovirus breakthrough events in a phase 2 prophylaxis trial of letermovir (aic246, mk 8228)","volume":"213","author":"Lischka","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1111\/ajt.15135","article-title":"Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection","volume":"18","author":"Cherrier","year":"2018","journal-title":"Am. J. Transplant. Off. J. Am. Soc. Transplant. Am. Soc. Transpl. Surg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: A phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect. Dis."},{"key":"ref_43","unstructured":"Shire (2018, September 26). Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-Assigned Treatment in Transplant Recipients with Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment with Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02931539."},{"key":"ref_44","unstructured":"Shire (2018, July 17). Study for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients, Available online: https:\/\/ClinicalTrials.gov\/show\/NCT02927067."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/00002030-200204120-00007","article-title":"HIV and cytomegalovirus viral load and clinical outcomes in aids and cytomegalovirus retinitis patients: Monoclonal antibody cytomegalovirus retinitis trial","volume":"16","author":"Jabs","year":"2002","journal-title":"AIDS (London)"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Wu, Y., Prager, A., Boos, S., Resch, M., Brizic, I., Mach, M., Wildner, S., Scrivano, L., and Adler, B. (2017). Human cytomegalovirus glycoprotein complex gh\/gl\/go uses pdgfr-alpha as a key for entry. PLoS Pathog., 13.","DOI":"10.1371\/journal.ppat.1006281"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1016\/j.bbmt.2018.07.013","article-title":"Repurposing nilotinib for cytomegalovirus infection prophylaxis after allogeneic hematopoietic stem cell transplantation: A single-arm, phase II trial","volume":"24","author":"Lin","year":"2018","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/978-1-62703-788-4_17","article-title":"Recent approaches and strategies in the generation of antihuman cytomegalovirus vaccines","volume":"1119","author":"Boppana","year":"2014","journal-title":"Methods Mol. Biol. (Clifton)"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"S196","DOI":"10.1093\/cid\/cit587","article-title":"Cytomegalovirus vaccines","volume":"57","author":"McVoy","year":"2013","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa0804749","article-title":"Vaccine prevention of maternal cytomegalovirus infection","volume":"360","author":"Pass","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1006\/viro.2002.1752","article-title":"Binding characteristics determine the neutralizing potential of antibody fragments specific for antigenic domain 2 on glycoprotein b of human cytomegalovirus","volume":"305","author":"Lantto","year":"2003","journal-title":"Virology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2014.03.015","article-title":"A new look at a poorly immunogenic neutralization epitope on cytomegalovirus glycoprotein B. Is there cause for antigen redesign?","volume":"60","author":"Ohlin","year":"2014","journal-title":"Mol. Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","article-title":"Cytomegalovirus glycoprotein-b vaccine with mf59 adjuvant in transplant recipients: A phase 2 randomised placebo-controlled trial","volume":"377","author":"Griffiths","year":"2011","journal-title":"Lancet (London)"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1128\/JVI.76.8.3748-3755.2002","article-title":"Sustained high frequencies of specific cd4 T cells restricted to a single persistent virus","volume":"76","author":"Sester","year":"2002","journal-title":"J. Virol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12185-016-2110-3","article-title":"Safety of asp0113, a cytomegalovirus DNA vaccine, in recipients undergoing allogeneic hematopoietic cell transplantation: An open-label phase 2 trial","volume":"105","author":"Mori","year":"2017","journal-title":"Int. J. Hematol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Samuel, E.R., Beloki, L., Newton, K., Mackinnon, S., and Lowdell, M.W. (2014). Isolation of highly suppressive cd25+foxp3+ t regulatory cells from g-csf-mobilized donors with retention of cytotoxic anti-viral ctls: Application for multi-functional immunotherapy post stem cell transplantation. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0085911"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0002-9378(97)80043-9","article-title":"Clinical uses of intravenous immunoglobulin in pregnancy","volume":"176","author":"Clark","year":"1997","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1086\/507634","article-title":"Placental enlargement in women with primary maternal cytomegalovirus infection is associated with fetal and neonatal disease","volume":"43","author":"Nigro","year":"2006","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/pd.1954","article-title":"Treatment of second trimester fetal cytomegalovirus infection with maternal hyperimmune globulin","volume":"28","author":"Moise","year":"2008","journal-title":"Prenat. Diagn."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/01.AOG.0000281669.19021.0f","article-title":"Resolution of hydrops secondary to cytomegalovirus after maternal and fetal treatment with human cytomegalovirus hyperimmune globulin","volume":"111","author":"Moxley","year":"2008","journal-title":"Obstet. Gynecol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJMoa043337","article-title":"Passive immunization during pregnancy for congenital cytomegalovirus infection","volume":"353","author":"Nigro","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/S0002-9378(99)70620-4","article-title":"Hyperimmunoglobulin therapy for a twin fetus with cytomegalovirus infection and growth restriction","volume":"180","author":"Nigro","year":"1999","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1056\/NEJMoa1310214","article-title":"A randomized trial of hyperimmune globulin to prevent congenital cytomegalovirus","volume":"370","author":"Revello","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/cid\/cis425","article-title":"Editorial commentary: Primary maternal cytomegalovirus infection during pregnancy: Do we have a treatment option?","volume":"55","author":"Adler","year":"2012","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1056\/NEJMc1405377","article-title":"Hyperimmune globulin to prevent congenital CMV infection","volume":"370","author":"Hamprecht","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Kagan, K.O., Enders, M., Schampera, M.S., Baeumel, E., Hoopmann, M., Geipel, A., Berg, C., Goelz, R., De Catte, L., and Wallwiener, D. (2018). Prevention of maternal-fetal transmission of cmv by hyperimmunoglobulin (hig) administered after a primary maternal cmv infectionin early gestation. Ultrasound Obstet. Gynecol. Off. J. Int. Soc. Ultrasound Obstet. Gynecol.","DOI":"10.1055\/s-0038-1671626"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.idc.2011.07.005","article-title":"Polyclonal immunoglobulins and hyperimmune globulins in prevention and management of infectious diseases","volume":"25","author":"Hsu","year":"2011","journal-title":"Infect. Dis. Clin. N. Am."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1399-0012.2007.00750.x","article-title":"Cmv-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: A meta-analysis","volume":"22","author":"Bonaros","year":"2008","journal-title":"Clin. Transplant."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Goldstein, G., Rutenberg, T.F., Mendelovich, S.L., Hutt, D., Oikawa, M.T., Toren, A., and Bielorai, B. (2017). The role of immunoglobulin prophylaxis for prevention of cytomegalovirus infection in pediatric hematopoietic stem cell transplantation recipients. Pediatr. Blood Cancer, 64.","DOI":"10.1002\/pbc.26420"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"E4997","DOI":"10.1073\/pnas.1316517110","article-title":"Pentameric complex of viral glycoprotein h is the primary target for potent neutralization by a human cytomegalovirus vaccine","volume":"110","author":"Freed","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"16082","DOI":"10.1038\/nmicrobiol.2016.82","article-title":"Platelet-derived growth factor-alpha receptor is the cellular receptor for human cytomegalovirus ghglgo trimer","volume":"1","author":"Kabanova","year":"2016","journal-title":"Nat. Microbiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1128\/JVI.00467-12","article-title":"Antibodies against the gh\/gl\/ul128\/ul130\/ul131 complex comprise the majority of the anti-cytomegalovirus (anti-cmv) neutralizing antibody response in cmv hyperimmune globulin","volume":"86","author":"Fouts","year":"2012","journal-title":"J. Virol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/S0378-3782(14)70011-8","article-title":"Role of human cytomegalovirus (hcmv)-specific antibody in hcmv-infected pregnant women","volume":"90","author":"Revello","year":"2014","journal-title":"Early Hum. Dev."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/rmv.1862","article-title":"Cytomegalovirus latency and reactivation: Recent insights into an age old problem","volume":"26","author":"Dupont","year":"2016","journal-title":"Rev. Med. Virol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1128\/JVI.01809-09","article-title":"Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gh\/gl\/ul128\u2013131a complex","volume":"84","author":"Macagno","year":"2010","journal-title":"J. Virol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Scrivano, L., Sinzger, C., Nitschko, H., Koszinowski, U.H., and Adler, B. (2011). HCMV spread and cell tropism are determined by distinct virus populations. PLoS Pathog., 7.","DOI":"10.1371\/journal.ppat.1001256"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.chom.2011.07.010","article-title":"Human cytomegalovirus escapes a naturally occurring neutralizing antibody by incorporating it into assembling virions","volume":"10","author":"Manley","year":"2011","journal-title":"Cell Host Microbe"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Ishida, J.H., Patel, A., Mehta, A.K., Gatault, P., McBride, J.M., Burgess, T., Derby, M.A., Snydman, D.R., Emu, B., and Feierbach, B. (2017). Phase 2 randomized, double-blind, placebo-controlled trial of rg7667, a combination monoclonal antibody, for prevention of cytomegalovirus infection in high-risk kidney transplant recipients. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.01794-16"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Deng, R., Wang, Y., Maia, M., Burgess, T., McBride, J.M., Liao, X.C., Tavel, J.A., and Hanley, W.D. (2018). Pharmacokinetics and exposure-response analysis of rg7667, a combination of two anticytomegalovirus monoclonal antibodies, in a phase 2a randomized trial to prevent cytomegalovirus infection in high-risk kidney transplant recipients. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.01108-17"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1128\/jvi.67.2.703-710.1993","article-title":"Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58\/116 (gb), as determined with human monoclonal antibodies","volume":"67","author":"Ohlin","year":"1993","journal-title":"J. Virol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1128\/AAC.00382-16","article-title":"In vitro characterization of human cytomegalovirus-targeting therapeutic monoclonal antibodies ljp538 and ljp539","volume":"60","author":"Patel","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1128\/AAC.02698-15","article-title":"A first-in-human study to assess the safety and pharmacokinetics of monoclonal antibodies against human cytomegalovirus in healthy volunteers","volume":"60","author":"Dole","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"460","DOI":"10.4161\/mabs.27760","article-title":"Multiplexed screening of natural humoral immunity identifies antibodies at fine specificity for complex and dynamic viral targets","volume":"6","author":"McCutcheon","year":"2014","journal-title":"mAbs"},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Potzsch, S., Spindler, N., Wiegers, A.K., Fisch, T., Rucker, P., Sticht, H., Grieb, N., Baroti, T., Weisel, F., and Stamminger, T. (2011). B cell repertoire analysis identifies new antigenic domains on glycoprotein b of human cytomegalovirus which are target of neutralizing antibodies. PLoS Pathog., 7.","DOI":"10.1371\/journal.ppat.1002172"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/infdis\/jiw487","article-title":"Maternal antibody responses and nonprimary congenital cytomegalovirus infection of hiv-1-exposed infants","volume":"214","author":"Bialas","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/infdis\/171.5.1115","article-title":"Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection","volume":"171","author":"Boppana","year":"1995","journal-title":"J. Infect. Dis."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.2353\/ajpath.2006.050482","article-title":"Maternal antibodies enhance or prevent cytomegalovirus infection in the placenta by neonatal fc receptor-mediated transcytosis","volume":"168","author":"Maidji","year":"2006","journal-title":"Am. J. Pathol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1128\/jvi.63.5.1995-2001.1989","article-title":"Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus","volume":"63","author":"Utz","year":"1989","journal-title":"J. Virol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1099\/0022-1317-73-9-2375","article-title":"Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies","volume":"73","author":"Meyer","year":"1992","journal-title":"J. Gen. Virol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.4049\/jimmunol.0901373","article-title":"Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from b cells of infected patients","volume":"183","author":"Collarini","year":"2009","journal-title":"J. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jim.2008.11.009","article-title":"Antibody discovery via multiplexed single cell characterization","volume":"341","author":"Harriman","year":"2009","journal-title":"J. Immunol. Methods"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1128\/AAC.04295-14","article-title":"A high-affinity native human antibody neutralizes human cytomegalovirus infection of diverse cell types","volume":"59","author":"Kauvar","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1080\/21645515.2016.1164376","article-title":"Preclinical evaluations of peptide-conjugate vaccines targeting the antigenic domain-2 of glycoprotein b of human cytomegalovirus","volume":"12","author":"Finnefrock","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_94","unstructured":"Janeway, C.A., Travers, P., Walport, M., and Shlomchik, M.J. (2001). Immunobiology: The Immune System in Health and Disease, Garland Science. [5th ed.]."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1038\/emboj.2008.179","article-title":"Germline v-genes sculpt the binding site of a family of antibodies neutralizing human cytomegalovirus","volume":"27","author":"Thomson","year":"2008","journal-title":"EMBO J."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.chom.2014.05.013","article-title":"Human responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangements","volume":"16","author":"Jackson","year":"2014","journal-title":"Cell Host Microbe"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.chom.2013.05.008","article-title":"Convergent antibody signatures in human dengue","volume":"13","author":"Parameswaran","year":"2013","journal-title":"Cell Host Microbe"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/j.1399-3062.2010.00563.x","article-title":"Lack of antibodies against the antigen domain 2 epitope of cytomegalovirus (cmv) glycoprotein b is associated with cmv disease after renal transplantation in recipients having the same glycoprotein h serotypes as their donors","volume":"13","author":"Ishibashi","year":"2011","journal-title":"Transpl. Infect. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1128\/CVI.00422-09","article-title":"Enzyme-linked immunosorbent assay for measurement of cytomegalovirus glycoprotein b antibody in serum","volume":"17","author":"Hackett","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1086\/515262","article-title":"Intragenic variability of human cytomegalovirus glycoprotein b in clinical strains","volume":"177","author":"Haberland","year":"1998","journal-title":"J. Infect. Dis."},{"key":"ref_101","unstructured":"Fu, T.-M., Tang, A., Wang, D., An, Z., Zhang, N., and Ha, S. (2017). CMV Neutralizing Antigen Binding Proteins. (Patent WO\/2017\/184562)."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Cui, X., Adler, S.P., Schleiss, M.R., Arav-Boger, R., Demmler Harrison, G.J., and McVoy, M.A. (2017). Cytomegalovirus virions shed in urine have a reversible block to epithelial cell entry and are highly resistant to antibody neutralization. Clin. Vaccine Immunol., 24.","DOI":"10.1128\/CVI.00024-17"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Mariame, B., Kappler-Gratias, S., Kappler, M., Balor, S., Gallardo, F., and Bystricky, K. (2018). Real-time visualization and quantification of human cytomegalovirus replication in living cells using the anchor DNA labeling technology. J. Virol.","DOI":"10.1101\/300111"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Cui, X., Freed, D.C., Wang, D., Qiu, P., Li, F., Fu, T.M., Kauvar, L.M., and McVoy, M.A. (2017). Impact of antibodies and strain polymorphisms on cytomegalovirus entry and spread in fibroblasts and epithelial cells. J. Virol., 91.","DOI":"10.1128\/JVI.01650-16"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"6808","DOI":"10.1128\/JVI.74.15.6808-6820.2000","article-title":"Human cytomegalovirus infection of placental cytotrophoblasts in vitro and in utero: Implications for transmission and pathogenesis","volume":"74","author":"Fisher","year":"2000","journal-title":"J. Virol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/12\/3982\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:33:03Z","timestamp":1760196783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/19\/12\/3982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,11]]},"references-count":105,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["ijms19123982"],"URL":"https:\/\/doi.org\/10.3390\/ijms19123982","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,11]]}}}